The gene-editing technology developer received further support from SoftBank Vision Fund 2 to advance its genomics drug discovery platform.
US-based genomic drug developer Tessera Therapeutics secured over $300m in series C funding from investors including internet and telecommunications group SoftBank’s Vision Fund 2 yesterday.
Hanwha Impact Partners, a branch of diversified conglomerate Hanwha, also took part in the round, as did life sciences-focused venture builder Flagship Pioneering, Alaska Permanent Fund Corporation and a subsidiary of Abu Dhabi Investment Authority.
The round was filled out Altitude Life Science Ventures, Cormorant Asset Management, Artis Ventures, Salt Fund, March Capital, T Rowe Price and Longevity Vision Fund along with all the company’s existing shareholders.
Founded in 2018 by Flagship Pioneering, Tessera utilises gene writing technology, which can write long and short DNA code and make small insertions and deletions, to develop drugs with the potential to cure genetic diseases or treat serious conditions like cancer.
The funding will help Tessera develop its gene writing platform and pursue the clinical development of multiple…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
